Table 2.
Women's Interagency Human Immunodeficiency Virus Study Entry Characteristics by Entry Tetrahydrocannabinol Use Category (n = 575)
| Variable | WIHS Entry THC Use |
||||
|---|---|---|---|---|---|
| None (n = 324) | Monthly Use (n = 141) | Weekly Use (n = 70) | Daily Use (n = 40) | P Value | |
| Age, y, mean (SD) | 40 (6) | 40 (7) | 39 (6) | 40 (6) | .61 |
| Race/ethnicity | |||||
| White, non-Hispanic | 14% (45) | 21% (29) | 19% (13) | 18% (7) | .76 |
| African American, non-Hispanic | 66% (214) | 60% (85) | 57% (40) | 60% (24) | |
| Hispanic | 19% (61) | 17% (24) | 21% (15) | 20% (8) | |
| HCV genotype 1 | 88% (239) | 88% (102) | 89% (50) | 87% (27) | .99 |
| HCV VL, log IU/mL, mean (SD) | 4.2 (1.1) | 6.1 (0.9) | 6.2 (0.8) | 6.1 (1.0) | .72 |
| CD4 count, cells/µL, median (IQR) | 354 (195–568) | 388 (257–564) | 378 (235–556) | 391 (236–664) | .25 |
| HIV VL, log IU/mL, mean (SD) | 4.2 (1.1) | 3.9 (1.1) | 4.0 (1.1) | 3.8 (1.3) | .03 |
| FIB-4 score, median (IQR) | 1.3 (1.0–1.9) | 1.2 (0.8–1.8) | 1.3 (1.0–1.9) | 1.2 (1.0–1.7) | .35 |
| BMI, kg/m2, mean (SD) | 26 (6) | 26 (6) | 26 (7) | 25 (5) | .71 |
| Hypertension | 30% (98) | 28% (39) | 31% (22) | 30% (12) | .93 |
| Diabetes | 18% (59) | 19% (27) | 16% (11) | 20% (8) | .93 |
| eGFR, mL/min/1.73 m2, median (IQR) | 87 (72–102) | 88 (72–101) | 87 (77–103) | 93 (77–112) | .42 |
| Cigarette use | 74% (241) | 89% (126) | 86% (60) | 83% (33) | .001 |
| Intravenous drug use | 19% (63) | 28% (39) | 31% (22) | 15% (6) | <.001 |
| Alcohol use, drinks/wk, median (IQR) | 0 (0–3) | 1 (0–9) | 1 (0–8) | 0.5 (0–4.5) | <.001 |
| Heavy alcohol use (>7 drinks/wk) | 12% (40) | 28% (39) | 26% (18) | 23% (9) | <.001 |
Data are presented as % (No.) unless otherwise indicated.
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis 4; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; SD, standard deviation; THC, tetrahydrocannabinol; VL, viral load; WIHS, Women's Interagency HIV Study.